A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

William J. Gradishar, Virginia Kaklamani, Tarini P. Sahoo, Dasappa Lokanatha, Vinod Raina, Shailesh Bondarde, Minish Jain, Sunhee Kwon Ro, Nathalie A. Lokker, Lee Schwartzberg

Producción científica: Article › revisión exhaustiva

85 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science